Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 5/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7327605 | 0.87 | TNKS (0.53) | TNKSTNKS2PARP1ADORA3KDM4E | |
| SCHEMBL7329545 | 0.86 | TNKS (0.41) | TNKSTNKS2PARP1KDM4EMAPT | |
| SCHEMBL7328378 | 0.85 | TNKS (0.38) | TNKSTNKS2PARP1ADORA3KDM4E | |
| SCHEMBL7336871 | 0.83 | MAP2K1 (0.44) | TNKSTNKS2PARP1ADORA3KDM4E | |
| SCHEMBL7337601 | 0.82 | TNKS (0.43) | TNKSTNKS2PARP1ADORA3 | |
| SCHEMBL7328423 | 0.81 | MAPT (0.42) | TNKSTNKS2PARP1KDM4EMAPT | |
| SCHEMBL7331035 | 0.80 | MAPT (0.48) | MAPTADORA1ADORA2AALDH1A1NPC1 | |
| SCHEMBL7337908 | 0.79 | SCN10A (0.38) | TNKSTNKS2PARP1NOTUMKDM4E | |
| SCHEMBL14469279 | 0.76 | EGFR (0.41) | PARP1ADORA1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15287401 | 0.70 | TNKS (0.65) | TNKSTNKS2PARP1ADORA3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-7432265-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-0726900-A1 | 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS | Aventis Pharma S.A. (FR) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012594-A1 | 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS | RHONE-POULENC RORER S.A. (FR) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063715-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | TNKS 205/4885TNKS2 180/4885PARP1 654/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | TNKS 254/4885TNKS2 234/4885PARP1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.